For patients living with end-stage renal disease, kidney transplantation represents the most effective treatment available — one that not only prolongs life but also dramatically improves its quality. Compared to dialysis, a successful kidney transplant reduces cardiovascular risk, restores a degree of metabolic normalcy, and allows many patients to return to active, productive lives. Yet transplantation is not a cure in the straightforward sense. It initiates a lifelong medical commitment that hinges on one central challenge: preventing the body’s immune system from recognizing and attacking the transplanted organ.
To accomplish this, transplant recipients must take immunosuppressive medications for the rest of their lives. While these drugs have made modern transplantation possible, they come with a well-documented burden of side effects — increased susceptibility to infections and cancers, metabolic disturbances, and, paradoxically, harm to the very organ they are meant to protect. The International Society of Nephrology has recognized the urgent need to move beyond decades-old treatment paradigms and is actively supporting the scientific community’s efforts to develop smarter, more targeted immunosuppressive strategies.
The Standard Regimen: Decades of Efficacy, Decades of Concerns
The backbone of kidney transplant immunosuppression has remained largely unchanged since the 1990s. Most patients are maintained on a triple-drug regimen consisting of:
- A calcineurin inhibitor (CNI) — typically tacrolimus or cyclosporine — which suppresses T-cell activation
- An antimetabolite — most commonly mycophenolate mofetil — which inhibits lymphocyte proliferation
- A corticosteroid — usually prednisone — which broadly dampens inflammatory responses
This combination has proven highly effective at preventing acute rejection in the first year after transplantation. However, its long-term track record is more complicated. One of the most significant concerns relates to the nephrotoxic effects of calcineurin inhibitors themselves. A landmark study by Nankivell and colleagues, published in the New England Journal of Medicine in 2003, used serial allograft biopsies to document that chronic CNI toxicity was nearly universal among long-term kidney transplant recipients, contributing to progressive interstitial fibrosis and tubular atrophy — changes that silently erode graft function over time.
In other words, the drugs used to protect the transplanted kidney can also, gradually, damage it. This irony has driven two decades of research into alternative and complementary strategies that preserve immune protection while reducing cumulative nephrotoxic exposure.
Belatacept and the Promise of CNI-Sparing Approaches
One of the most significant advances to emerge from this research effort is belatacept, a selective T-cell costimulation blocker that works through a fundamentally different mechanism than calcineurin inhibitors. Rather than broadly suppressing T-cell signaling, belatacept targets a specific activation pathway by blocking the interaction between CD80/CD86 molecules on antigen-presenting cells and the CD28 receptor on T cells. Without this costimulatory signal, T cells cannot mount a full immune response against the graft.
The clinical evidence for belatacept’s effectiveness comes primarily from the BENEFIT and BENEFIT-EXT trials, led by Vincenti and colleagues and published in the New England Journal of Medicine in 2010 and American Journal of Transplantation in 2016. These trials compared belatacept-based maintenance to cyclosporine-based regimens and found that belatacept recipients demonstrated superior renal function trajectories at five and seven years post-transplantation. The estimated glomerular filtration rate (eGFR) — the key measure of kidney function — was meaningfully higher in the belatacept group, suggesting that avoiding CNI exposure over time allows the transplanted kidney to function better.
Belatacept does carry its own considerations: it is administered intravenously on a monthly schedule, which requires clinic visits, and early trials noted a higher incidence of acute rejection, particularly in Epstein-Barr virus–seronegative patients. Nevertheless, its approval and uptake have validated the concept of CNI-sparing maintenance, and ISN (International Society of Nephrology) has highlighted this development as part of its educational outreach on evolving transplant immunosuppression.
The Humoral Immune System: A New Frontier in Rejection Biology
While T-cell–mediated rejection was long considered the primary immunological threat to transplanted kidneys, the past two decades have reframed our understanding of long-term graft loss. Increasingly, evidence points to the humoral immune system — particularly antibodies directed against donor-specific antigens — as a central driver of chronic rejection and eventual graft failure.
Understanding Donor-Specific Antibodies (DSA)
Donor-specific antibodies (DSA) are immunoglobulins produced by the recipient’s B cells and plasma cells that recognize and bind to human leukocyte antigens (HLA) expressed on the surface of donor kidney cells. When DSAs develop after transplantation — a process known as de novo DSA formation — they can initiate a cascade of immune injury that damages the microvasculature of the graft, leading to a condition called antibody-mediated rejection (AMR).
The DESCARTES observational study, along with data from the Collaborative Transplant Study registry, has been instrumental in defining the natural history of de novo DSA development. These large-scale observational datasets have demonstrated that the presence of DSA is strongly associated with the development of chronic AMR and, ultimately, graft loss — often years after transplantation, when the patient may feel clinically well. This delayed and insidious nature of humoral rejection makes early detection and monitoring critically important.
Current KDIGO (Kidney Disease: Improving Global Outcomes) guidelines on kidney transplantation now incorporate recommendations for DSA monitoring, reflecting the epidemiological evidence generated by these studies. The International Society of Nephrology supports the dissemination and implementation of these guidelines globally, particularly in regions where transplant programs may have limited access to specialized immunological testing.
Strategies to Combat Antibody-Mediated Rejection
Because AMR has been identified as a major cause of late graft loss, considerable research effort has gone into developing therapeutic strategies targeting the humoral immune pathway. This remains one of the most active and challenging frontiers in transplant medicine.
Complement Inhibition
One approach involves targeting the complement system — a network of proteins that amplifies immune injury once antibodies bind to their targets. Eculizumab, a monoclonal antibody that blocks the complement protein C5, has been studied as a rescue therapy for severe AMR. Case series and small prospective studies, published in journals including Transplantation and American Journal of Transplantation, have reported encouraging signals in patients with refractory AMR, though the evidence base remains limited and the therapy is not yet part of standard care.
Plasma Cell–Targeted Therapies
A more direct approach to reducing DSA levels involves targeting the plasma cells that produce them. Two investigational strategies have attracted particular attention:
- Bortezomib, a proteasome inhibitor originally developed for multiple myeloma, depletes plasma cells and has been used in small studies of AMR with mixed results.
- Daratumumab, an anti-CD38 monoclonal antibody also used in hematological malignancies, targets a surface marker highly expressed on plasma cells and has shown promise in early-phase investigations of DSA reduction and AMR treatment.
A 2021 commentary by Schinstock and colleagues in Kidney International reviewed the evidence for these plasma cell–directed approaches and highlighted their potential while acknowledging that robust randomized trial data are still lacking. The field is at an early but exciting stage, and the ISN has called for international collaboration to generate the higher-quality evidence needed to establish these agents in clinical practice.
The Banff Classification: A Shared Language for Rejection
Effective treatment of rejection requires accurate diagnosis, and accurate diagnosis requires a standardized framework that transplant pathologists worldwide can apply consistently. This is the role of the Banff classification system — an internationally agreed-upon set of criteria for categorizing the histopathological findings in transplant kidney biopsies.
Originally developed in 1991 and updated through numerous international conferences, the Banff classification provides precise definitions for different types and grades of rejection, including T-cell–mediated rejection, antibody-mediated rejection, and borderline changes. The most recent update, published in 2022 by Loupy and colleagues in American Journal of Transplantation, incorporated advances in molecular diagnostics and refined the criteria for AMR phenotyping to reflect current understanding of rejection biology.
The International Society of Nephrology has actively supported the global dissemination of Banff criteria, recognizing that consistent histopathological classification is not merely an academic exercise — it is a prerequisite for comparable clinical trials, reliable outcome data, and equitable patient care across different healthcare systems. Without a shared diagnostic language, it becomes impossible to aggregate data meaningfully or compare outcomes across centers and countries.
Key Milestones in Kidney Transplant Immunosuppression
| Year | Development | Significance |
|---|---|---|
| 2003 | Nankivell et al., NEJM — CNI nephrotoxicity documented via serial biopsies | Established the long-term harm of calcineurin inhibitors on allograft histology |
| 2010 | BENEFIT trial (Vincenti et al., NEJM) — Belatacept vs. cyclosporine | Demonstrated superior 5-year renal function with belatacept-based CNI-sparing regimen |
| 2016 | BENEFIT-EXT 7-year follow-up — American Journal of Transplantation | Confirmed sustained eGFR advantage with belatacept over cyclosporine |
| 2021 | Schinstock et al., Kidney International — Review of plasma cell–targeted therapies | Summarized investigational AMR treatments including bortezomib and daratumumab |
| 2022 | Loupy et al., American Journal of Transplantation — Banff 2022 update | Updated histopathological framework for rejection phenotyping with molecular integration |
Biomarker-Driven Immunosuppression: The Future of Personalized Transplant Care
Perhaps the most transformative concept reshaping transplant immunosuppression today is the idea of individualization — tailoring the intensity and composition of the immunosuppressive regimen to the specific immunological risk profile of each patient, rather than applying a one-size-fits-all protocol.
This vision depends on the development and validation of reliable biomarkers: measurable indicators that reflect the state of immune activity, rejection risk, or graft health. Several categories of biomarkers are under active investigation:
- Donor-specific antibodies (DSA) — as discussed, DSA monitoring is already incorporated into clinical guidelines and represents the most mature biomarker in this field
- Donor-derived cell-free DNA (dd-cfDNA) — fragments of donor DNA detectable in the recipient’s blood, which rise when the graft is under immune attack; this non-invasive liquid biopsy approach is gaining clinical traction
- Gene expression profiling — molecular analysis of biopsy tissue to identify rejection signatures beyond what conventional microscopy can reveal
- Urinary biomarkers — proteins and gene transcripts detectable in urine that may reflect early tubular or glomerular injury
The ISN (International Society of Nephrology) has called for international collaboration in establishing biomarker-driven immunosuppression protocols, recognizing that no single center or country has the patient volumes needed to validate these tools across diverse populations. Multicenter registries, data-sharing agreements, and coordinated trial designs are essential to generating the evidence that would allow biomarkers to move from research tools to clinical standard of care.
Global Equity in Transplant Immunosuppression
Any discussion of advances in transplant immunosuppression must acknowledge the profound global inequities that exist in access to both transplantation itself and the medications required for long-term graft survival. While centers in high-income countries may offer belatacept infusions, routine DSA monitoring, and advanced molecular diagnostics, many transplant programs in low- and middle-income countries continue to face shortages of even basic immunosuppressive agents.
The International Society of Nephrology has long recognized this disparity as a central challenge for global nephrology. Through advocacy, educational initiatives, and partnerships with regional nephrology societies, ISN works to expand access to transplantation and support evidence-based immunosuppression protocols in resource-limited settings. Ensuring that advances in CNI-sparing therapy, DSA monitoring, and Banff-standardized diagnostics are not confined to wealthy transplant centers is both an ethical imperative and a scientific one — global data diversity strengthens the evidence base for the entire field.
What Comes Next: Key Research Priorities
The transplant immunosuppression landscape is evolving rapidly, but several critical questions remain unanswered. Among the most pressing research priorities identified by the transplant nephrology community are:
- Developing robust randomized controlled trial evidence for anti-AMR therapies, including complement inhibitors and plasma cell–directed agents
- Validating dd-cfDNA and other liquid biopsy biomarkers in large, diverse populations
- Establishing safe and effective protocols for immunosuppression minimization or withdrawal in low-risk recipients
- Understanding the determinants of immune tolerance — the rare but remarkable state in which a recipient’s immune system accepts the donor kidney without ongoing medication
- Improving long-term graft survival beyond the first decade, which remains an area where outcomes have been disappointing despite short-term improvements
The International Society of Nephrology continues to support research in all these areas through its publications, educational programs, and advocacy for increased funding and international scientific collaboration.
Conclusion: Progress Built on Science, Driven by Collaboration
Kidney transplantation has transformed the lives of millions of patients with end-stage renal disease, and the science of transplant immunosuppression has advanced considerably since the era when rejection was the primary clinical fear. Today, the field confronts more
nuanced challenges: reducing the long-term toxicity of calcineurin inhibitors, detecting and treating antibody-mediated rejection before irreversible damage occurs, and personalizing immunosuppressive regimens to the biology of each individual patient and graft.
The path forward is neither simple nor short. It requires continued investment in clinical trials, the development and validation of new biomarkers, global standardization of diagnostic criteria through frameworks like the Banff classification, and a sustained commitment to equitable access. The International Society of Nephrology stands at the intersection of these efforts — convening the global nephrology community, disseminating best practices, and advocating for the resources and international collaboration that this complex field demands. As science continues to illuminate the immunological mechanisms that determine graft fate, and as new therapeutic tools move from bench to bedside, the ISN remains committed to ensuring that these advances reach every patient who needs them, wherever they may be in the world.